Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination

被引:52
作者
Grant, Lindsay R. [1 ]
Slack, Mary P. E. [2 ]
Theilacker, Christian [3 ]
Vojicic, Jelena [4 ]
Dion, Stephane [4 ]
Reinert, Ralf Rene [5 ]
Jodar, Luis [1 ]
Gessner, Bradford D. [1 ]
机构
[1] Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426 USA
[2] Griffith Univ, Sch Med & Dent, Gold Coast Campus, Southport, Qld, Australia
[3] Pfizer Pharma GmbH, Berlin, Germany
[4] Pfizer Canada ULC, Montreal, PQ, Canada
[5] Pfizer Inc, Paris, France
关键词
children; invasive pneumococcal disease; pneumococcal conjugate vaccines; serotype distribution; streptococcus pneumoniae; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; 13-VALENT; IMMUNOGENICITY; POPULATION; PREVENTION; ENGLAND; BURDEN; ADULTS; WALES;
D O I
10.1093/cid/ciac475
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococcal serotype distribution in children from high-income countries was assessed. Much of the burden of invasive pneumococcal disease (IPD) is due to serotypes in PCV15 and PCV20; including these pneumococcal conjugate vaccines (PCVs) into existing pediatric immunization programs may help reduce IPD incidence. Background The introduction and adoption of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIPs) has led to large decreases in invasive pneumococcal disease (IPD) incidence caused by vaccine serotypes. Despite these reductions, the global IPD burden in children remains significant. Methods We collected serotype-specific IPD data from surveillance systems or hospital networks of all 30 high-income countries that met inclusion criteria. Data sources included online databases, surveillance system reports, and peer-reviewed literature. Percentage of serotyped cases covered were calculated for all countries combined and by PCV type in the pediatric NIP. Results We identified 8012 serotyped IPD cases in children <5 or <= 5 years old. PCV13 serotype IPD caused 37.4% of total IPD cases, including 57.1% and 25.2% for countries with PCV10 or PCV13 in the pediatric NIP, respectively, most commonly due to serotypes 3 and 19A (11.4% and 13.3%, respectively, across all countries). In PCV10 countries, PCV15 and PCV20 would cover an additional 45.1% and 55.6% of IPD beyond serotypes contained in PCV10, largely due to coverage of serotype 19A. In PCV13 countries, PCV15 and PCV20 would cover an additional 10.6% and 38.2% of IPD beyond serotypes contained in PCV13. The most common IPD serotypes covered by higher valency PCVs were 10A (5.2%), 12F (5.1%), and 22F and 33F (3.5% each). Conclusions Much of the remaining IPD burden is due to serotypes included in PCV15 and PCV20. The inclusion of these next generation PCVs into existing pediatric NIPs may further reduce the incidence of childhood IPD.
引用
收藏
页码:E1062 / E1070
页数:9
相关论文
共 40 条
[1]  
[Anonymous], CLIN MICROBIOL INFEC
[2]   Burden of Streptococcus pneumoniae Sepsis in Children After Introduction of Pneumococcal Conjugate Vaccines: A Prospective Population-based Cohort Study [J].
Asner, Sandra A. ;
Agyeman, Philipp K. A. ;
Gradoux, Eugenie ;
Posfay-Barbe, Klara M. ;
Heininger, Ulrich ;
Giannoni, Eric ;
Crisinel, Pierre A. ;
Stocker, Martin ;
Bernhard-Stirnemann, Sara ;
Niederer-Loher, Anita ;
Kahlert, Christian R. ;
Hasters, Paul ;
Relly, Christa ;
Baer, Walter ;
Aebi, Christoph ;
Schlapbach, Luregn J. ;
Berger, Christoph .
CLINICAL INFECTIOUS DISEASES, 2019, 69 (09) :1574-1580
[3]   Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis [J].
Balsells, Evelyn ;
Guillot, Laurence ;
Nair, Harish ;
Kyaw, Moe H. .
PLOS ONE, 2017, 12 (05)
[4]   Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease [J].
Berman-Rosa, Melissa ;
O'Donnell, Shauna ;
Barker, Mackenzie ;
Quach, Caroline .
PEDIATRICS, 2020, 145 (04)
[5]   Application of a Pneumococcal Serotype-specific Urinary Antigen Detection Test for Identification of Pediatric Pneumonia in Burkina Faso [J].
Bountogo, Mamadou ;
Sanogo, Bintou ;
Pride, Michael W. ;
Jiang, Qin ;
Nikiema, Zakari ;
Njanpop-Lafourcade, Berthe-Marie ;
Ouedraogo, Abdou Salam ;
van der Linden, Mark P. G. ;
Moisi, Jennifer ;
Tall, Haoua ;
Essoh, Alima ;
Betsem, Edouard ;
Gessner, Bradford D. ;
Meda, Nicolas .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (05) :418-425
[6]  
Centers for Disease Control and Prevention, Streptococcus pneumoniae
[7]   Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries [J].
Cohen, Robert ;
Cohen, Jeremie Francois ;
Chalumeau, Martin ;
Levy, Corinne .
EXPERT REVIEW OF VACCINES, 2017, 16 (06) :625-640
[8]   Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial [J].
Dagan, Ron ;
Patterson, Scott ;
Juergens, Christine ;
Greenberg, David ;
Givon-Lavi, Noga ;
Porat, Nurith ;
Gurtman, Alejandra ;
Gruber, William C. ;
Scott, Daniel A. .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (07) :952-962
[9]   Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study [J].
Desmet, Stefanie ;
Lagrou, Katrien ;
Wyndham-Thomas, Chloe ;
Braeye, Toon ;
Verhaegen, Jan ;
Maes, Piet ;
Fieuws, Steffen ;
Peetermans, Willy E. ;
Blumental, Sophie .
LANCET INFECTIOUS DISEASES, 2021, 21 (01) :127-136
[10]   Pneumococcal infection in adults: burden of disease [J].
Drijkoningen, J. J. C. ;
Rohde, G. G. U. .
CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 :45-51